B7-H3/CD276: An Emerging Cancer Immunotherapy

Zhou, Wu-Tong; Jin, Weilin

doi:10.3389/fimmu.2021.701006

Cited by 107 publications

(66 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the immune-checkpoint gene expression analysis found the low-risk group showed an upregulation of two tumor- necrosis factor co-stimulating factors, CD27 and CD40, both of which are widely expressed in antigen-presenting cells or T/B cells, and have been verified to facilitate tumor cell elimination (Vonderheide, 2020;Wasiuk et al, 2021). Another important immune-checkpoint gene CD276, also known as B7-H3, has been observed to be up-regulated in the high-risk group, which is consistent with the previous evidence that CD276 is generally overexpressed in tumor tissues compared to normal tissues and could lead to worse survival (Zhou and Jin, 2021). Importantly, the external validation using IMvigor210 data revealed the capability of our signature to identify patients who could potentially benefited from immune-checkpoint inhibitor treatment, by showing that the low-risk group had more inflamed phenotype and less desert phenotype.…”

Section: Discussionsupporting

confidence: 88%

A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer

Zheng

Zhou

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

Immunotherapy has been a milestone for muscle-invasive bladder cancer (MIBC), but only a small portion of patients can benefit from it. Therefore, it is crucial to develop a robust individualized immune-related signature of MIBC to identify patients potentially benefiting from immunotherapy. The current study identified patients from the Cancer Genome Atlas (TCGA) and immune genes from the ImmPort database, and used improved data analytical methods to build up a 45 immune-related gene pair signature, which could classify patients into high-risk and low-risk groups. The signature was then independently validated by a Gene Expression Omnibus (GEO) dataset and IMvigor210 data. The subsequent analysis confirmed the worse survival outcomes of the high-risk group in both training (p < 0.001) and validation cohorts (p = 0.018). A signature-based risk score was proven to be an independent risk factor of overall survival (p < 0.001) and could predict superior clinical net benefit compared to other clinical factors. The CIBERSORT algorithm revealed the low-risk group had increased CD8+ T cells plus memory-activated CD4+ T-cell infiltration. The low-risk group also had higher expression of PDCD1 (PD-1), CD40, and CD27, and lower expression of CD276 (B7-H3) and PDCD1LG2 (PD-L2). Importantly, IMvigor210 data indicated that the low-risk group had higher percentage of “inflamed” phenotype plus less “desert” phenotype, and the survival outcomes were significantly better for low-risk patients after immunotherapy (p = 0.014). In conclusion, we proposed a novel and promising prognostic immune-related gene pair (IRGP) signature of MIBC, which could provide us a panoramic view of the tumor immune microenvironment of MIBC and independently identify MIBC patients who might benefit from immunotherapy.

show abstract

Section: Discussionsupporting

confidence: 88%

A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer

Zheng

Zhou

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…In this study, three immune checkpoints (PD-1, B7-H3, and VSIR) were shown to be expressed higher among patients with high-risk score. B7-H3, also known as CD276, is an immune checkpoint molecule and immunoregulatory protein, which participates in tumor microenvironment shaping and development ( 21 ). VSIR, also known as VISTA, is a well-established immune regulatory receptor functioning like a homeostatic regulator that actively normalizes immune responses ( 22 ).…”

Section: Discussionmentioning

confidence: 99%

Role of a Pyroptosis-Related lncRNA Signature in Risk Stratification and Immunotherapy of Ovarian Cancer

Zhang

Yan

2022

Front. Med.

View full text Add to dashboard Cite

Background: Pyroptosis is a newly recognized form of cell death. Emerging evidence has suggested the crucial role of long non-coding RNAs (lncRNAs) in the tumorigenesis and progression of ovarian cancer (OC). However, there is still poor understanding of pyroptosis-related lncRNAs in OC.Methods: The TCGA database was accessed for gene expression and clinical data of 377 patients with OC. Two cohorts for training and validation were established by random allocation. Correlation analysis and Cox regression analysis were performed to identify pyroptosis-related lncRNAs and construct a risk model.Results: Six pyroptosis-related lncRNAs were included in the final signature with unfavorable survival data. Subsequent ROC curves showed promising predictive value of patient prognosis. Further multivariate regression analyses confirmed the signature as an independent risk factor in the training (HR: 2.242, 95% CI: 1.598–3.145) and validation (HR: 1.884, 95% CI: 1.204–2.95) cohorts. A signature-based nomogram was also established with a C-index of.684 (95% CI: 0.662–0.705). Involvement of the identified signature in multiple immune-related pathways was revealed by functional analysis. Moreover, the signature was also associated with higher expression of three immune checkpoints (PD-1, B7-H3, and VSIR), suggesting the potential of the signature as an indicator for OC immunotherapies.Conclusion: This study suggests that the identified pyroptosis-related lncRNA signature and signature-based nomogram may serve as methods for risk stratification of OC. The signature is also associated with the tumor immune microenvironment, potentially providing an indicator for patient selection of immunotherapy in OC.

show abstract

“…Furthermore, preclinical studies demonstrated the therapeutic efficacy of PD-1 blockade alone [ 114 , 115 ] or in combination with anti-CTLA-4 vaccination [ 116 ] in NB animal models. NB cells also express the B7-H3 (CD276) antigen, which is a glycoprotein that belongs to the B7 family of molecules that has been described as an IC molecule in the last years in different solid tumors [ 117 , 118 ]. B7-H3 is expressed on metastatic NB cells from patients, and its pro-tumoral effect is related to the inhibition of NK-mediated tumor cell lysis [ 119 ].…”

Section: Hla-g and Other Ic In Pediatric Solid Tumorsmentioning

confidence: 99%

HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies

Morandi

Airoldi

2022

IJMS

View full text Add to dashboard Cite

HLA-G is an HLA-class Ib molecule that is involved in the establishment of tolerance at the maternal/fetal interface during pregnancy. The expression of HLA-G is highly restricted in adults, but the de novo expression of this molecule may be observed in different hematological and solid tumors and is related to cancer progression. Indeed, tumor cells expressing high levels of HLA-G are able to suppress anti-tumor responses, thus escaping from the control of the immune system. HLA-G has been proposed as an immune checkpoint (IC) molecule due to its crucial role in tumor progression, immune escape, and metastatic spread. We here review data available in the literature in which the interaction between HLA-G and other IC molecules is reported, in particular PD-1, CTLA-4, and TIM-3, but also IDO and TIGIT. Clinical trials using monoclonal antibodies against HLA-G and other IC are currently ongoing with cancer patients where antibodies and inhibitors of PD-1 and CTLA-4 showed encouraging results. With this background, we may envisage that combined therapies using antibodies targeting HLA-G and another IC may be successful for clinical purposes. Indeed, such immunotherapeutic protocols may achieve a better rescue of effective anti-tumor immune response, thus improving the clinical outcome of patients.

show abstract

B7-H3/CD276: An Emerging Cancer Immunotherapy

Cited by 107 publications

References 111 publications

A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer

A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer

Role of a Pyroptosis-Related lncRNA Signature in Risk Stratification and Immunotherapy of Ovarian Cancer

HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies

Contact Info

Product

Resources

About